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Background: Clinical trials report beneﬁts of the xanthophylls lutein and zeaxanthin for skin health. Here
a keratinocyte culture was used to investigate the effects of in vitro xanthophyll treatment on gene ex-
pression and biochemical pathways.
Methods: We employed the EpiDerm tissue model, Affymetrix Human Genome Array U113, bioinfor-
matics analyses, qPCR validation and biochemical assays for glycosaminoglycans.
Results: We discovered 176 genes were signiﬁcantly (po0.05) down-regulated (log 2FC42) and 47
genes were signiﬁcantly up-regulated. Among the down-regulated genes we validated by qPCR marked
reduction in expression of peptidase inhibitors. Bioinformatic analysis of the up-regulated genes im-
plicated biosynthetic pathways for glycosaminoglycans. We assayed but found no increase in production
of sulfated glycosaminoglycans, however there was a signiﬁcant increase in biosynthesis of hyaluronic
acid, a non-sulfated glycan.
Conclusions: The pattern of xanthophyll-regulated genes and the resulting biochemical responses can be
linked with the responses observed in clinic trials.
General signiﬁcance: Skin health beneﬁts from xanthophyll supplementation and this study reveals
molecular mechanisms for some of the effects.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Lutein and zeaxanthin are xanthophylls, a class of isomeric
tetraterpenoid carotenoids characterized by their yellow color and
hydroxyl group substituents. Like other carotenoids, xanthophylls
serve as pigments in photosynthetic organisms and are not syn-
thesized by animals and therefore must be obtained from the diet,
typically from leafy vegetables such as spinach and kale, or egg
yolks where they are concentrated from feed sources [1–4].
Lutein and zeaxanthin become concentrated in the macea lutea,
the focal center of the eye, and are measured as macular pigment
optical density. Lutein and zeaxanthin absorb blue light to reduce
oxidative stress in the retina and are believed to function as an-
tioxidants that protect photoreceptor cells against free radicals
produced by light and high oxygen tension [5]. A major clinical
trial (AREDS2) sponsored by the US National Institutes of Health
showed consumption of supplemental lutein and zeaxanthin re-
duced the risk of age-related macular degeneration and improvedr B.V. This is an open access article
).visual acuity, particularly contrast acuity [6]. Largely driven by the
results of AREDS2, lutein and zeaxanthin are currently marketed as
nutritional supplements for their role in macular health.
The antioxidative properties of xanthophylls also are believed
to play a role in protecting the skin against light-induced damage.
Lutein and zeaxanthin are found in the skin as a result of dietary
intake. The ingestion and deposition of dietary antioxidants is one
form of protection against radiation, as other protective measures,
such as melanin protection, are triggered only after light-induced
damage occurs in the skin [7,8]. The visible wavelengths absorbed
by lutein and zeaxanthin are relatively high energy, and although
not in the ultraviolet range, are capable of producing free radicals
in the skin [8]. Xanthophylls are thought to protect against pho-
todamage in the skin in the same manner as they are thought to
function in the retina [9]. Ingested lutein and zeaxanthin have thus
far been shown to protect against UV-induced skin damage, in-
cluding edema and hyperplasia, in animals [10].
A 2002 clinical trial conducted by Palombo et al. [11] demon-
strated the efﬁcacy of lutein and zeaxanthin in improving skin
health. Physiological properties of skin were measured in women
given oral and/or topical treatment of a lutein/zeaxanthin combi-
nation: (1) surface lipid production, (2) lipid peroxidation,under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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dration. Both oral and topical supplementation had a positive ef-
fect on all these variables measured individually, with the largest
effects found in response to the combination of oral plus topical
treatments. Oral and topical administration of xanthophylls in-
dividually and combined also moderately increased photo-
protective activity within the ﬁrst two weeks of treatment. Topical
treatment proved most effective in increasing skin elasticity. Pa-
lombo et al. attributed the increased photoprotective activity by
lutein and zeaxanthin treatment to the protection they provide
against free radicals. They also attributed the decrease in lipid
peroxidation to the antioxidative effects of these xanthophylls [11].
We wanted to test the hypothesis that the beneﬁcial effects on
skin observed clinically were not simply due to the antioxidant
and light absorbing properties of the xanthophylls. Xanthophylls
chemically resemble retinoids that act though nuclear hormone
receptors. Unlike retinoids, xanthophylls are not converted into
vitamin A, nonetheless we suspected that they could alter patterns
of gene expression. In this study, we analyzed gene expression
proﬁles using EpiDerm an in vitro model of human skin and also
tested for some biochemical changes that corresponded to the
genes most affected by lutein and zeaxanthin.2. Materials and methods
2.1. Cell culture and reagents
EpiDerm (EPI-212) tissue models of human keratinocytes were
purchased from MatTek Corporation with provided DMEM med-
ium. EpiDerm samples were cultured in the medium supple-
mented with ﬁnal concentrations of 5 μM lutein and 1 μM zeax-
anthin or the corresponding volume of DMSO at 37 °C for 24 h. We
chose these conditions because xanthophylls have been detected
at micromolar concentrations in human plasma and blood [6,12]
and the 5:1 ratio has been used as a dietary supplement in clinical
studies [6] and adopted as the commercial supplement formula-
tion. Puriﬁed lutein and zeaxanthin dissolved in DMSO were
provided by Kemin Industries, Des Moines, IA.
2.2. Affymetrix microarray gene chip analysis
Total RNA was extracted from EpiDerm samples using RNeasy
Mini Kit (QIAGEN) and submitted to the UVA Biomolecular Re-
search Facility for Affymetrix gene chip analysis using the Human
Genome Array U113. Data was analyzed by the UVA Bioinformatics
Core. All data processing and analysis was done using R and Bio-
conductor packages. Affymetrix CEL ﬁles were imported using the
affy package. Expression intensities were summarized, normalized,
and transformed using Robust Multiarray Average algorithm [13].
Probesets were annotated using the 'GEOquery' package. For ex-
amining differential gene expression, we ﬁt a linear model with
empirical-Bayes moderated standard errors using the limma
package in R.
2.3. Pathway analysis
We employed three bioinformatic tools in the analysis of the
Affymetrix array data. The ﬁrst of these was Gene Set Enrichment
Analysis (GSEA) that uses all genes and their fold change obtained
from the Affymetrix analysis and computes an enrichment group
for gene groupings [14]. A second tool was the DAVID functional
annotation tool, developed by the Laboratory of Im-
munopathogenesis and Bioinformatics for the National Institute of
Allergy and Infectious Diseases. It conducts a search using a user-
inputed list of genes to identify known pathways containing thosegenes [15,16]. The third tool was the ConsensusPathDB (CPDB)
from the Max Planck Institute for Molecular Genetics, which in-
cludes a gene set over-representation analysis tool. It takes a user-
deﬁned gene list and searches among over-representation sets. A
p-value and q-value are calculated for each set, and the involved
genes are represented [17,18]. The oPOSSUM algorithm was used
to perform single-site transcription factor analysis, which pro-
duced a Z score, which is the number of standard deviations above
or below the expected rate of occurrence of a transcription factor
binding site [19–21].
2.4. RT-PCR validation
RNA was extracted from one biological replicate of Epiderm
samples, control and xanthophyll treated, using the RNeasy Mini
Kit. The puriﬁed RNA was used to synthesize cDNA, which was
analyzed using the Human Drug Metabolism RT2 Proﬁler PCR array
from Qiagen, which contained 16 of the downregulated genes,
based on the Affymetrix expression data. We analyzed the cDNA
and compared fold change (FC) in the relevant genes. Another
independent RT-PCR assay was performed to verify the results of
the gene expression analysis. This consisted of a custom set of
primers for the top ten (most upregulated) and bottom ten (most
downregulated) genes from the Affymetrix data, based on log ra-
tios. This assay was done in duplicate for the control and xan-
thophyll treated samples.
2.5. Blyscan dye-binding assay
Sulfated glycosaminoglycan (GAG) production was measured
using the Blyscan assay developed by Barbosa et al. [22]. Triplicate
samples of EpiDerm tissue were treated with lutein/zeaxanthin
combination for 0, 1, 2, or 3 days. Each individual tissue sample
was removed from its ﬁlter insert and digested using papain fol-
lowing the manufacturer's instructions to release GAGs from the
tissue. The Blyscan dye-binding assay was performed on both the
digested tissue and culture media of each sample to determine the
total GAG content. The Blyscan assay uses speciﬁc binding of 1,9-
dimethylmethylene blue to sulfated GAGs and isolation of the
GAG–dye complex as a pellet, followed by dissociation and
quantiﬁcation using spectrophotometry. Absorbance was mea-
sured with a 650 nm ﬁlter, near the maximum absorbance of the
dye at 656 nm.
2.6. 35S-sulfate labeling assay
Triplicate EpiDerm samples were incubated with lutein/zeax-
anthin combination for 0, 1, or 3 days, in medium with 0.7 mCi of
35S-sulfate. The tissue samples in the ﬁlter inserts were washed
three times with PBS and the washes monitored for removal of
unincorporated radioactivity. The tissues were removed from the
inserts and digested with papain, then entire sample suspended in
Scintisafe Econo 1 Cocktail and the 35S content determined using a
Beckman LS-6500 liquid scintillation counter.
2.7. Hyaluranon assay
Quantiﬁcation of hyaluranon (HA) was performed using an
enzyme-linked competitive binding assay from R&D Systems.
Triplicate EpiDerm samples were treated with lutein/zeaxanthin
combination for 24 h, the media was removed and assayed un-
diluted and diluted 10 . Precoated 96-well plates were used to
bind HA, which was detected by absorbance at 450 nm. A cali-
bration curve was constructed from commercial HA standard
provided. The undiluted samples exceeded the linear range, so
10 diluted samples, which were in the linear range, were used to
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3.1. Effects of xanthophylls
Supplementation on gene expression in human keratinocytes
The human EpiDerm keratinocyte culture system is an estab-
lished in vitro model for human skin [23]. Using the Epi-212
multiwell plate, three wells were supplemented with lutein plus
zeaxanthin and three wells were treated with DMSO as control for
24 h at 37 °C. The individual tissue specimens were extracted and
RNA was isolated. Puriﬁed RNA was proﬁled using Agilent micro-
capillary electrophoresis system to ensure quality, with RINZ9.
Gene expression analysis was performed using Affymetrix Human
Genome Array U133. Hierarchical clustering and principal com-
ponent analysis (PCA) (Fig. 1A and B) showed clear separation
between the control and experimental samples and similarities
amongst the replicates.
A volcano plot was used to graphically depict the fold change
(log FC on the X axis) and statistical signiﬁcance ( log10(p-value) on
the Y axis) of the differences in gene expression (Fig. 1C). The green
dots in the upper right and left quadrants of the volcano plot show
the 47 most up-regulated genes and the 176 most down-regulated
genes, deﬁned as |log(FC)|42 and log10(adj. p-value)o0.05.
3.2. Pathway analysis
Gene Set Enrichment Analysis (GSEA) uses all genes from the
microarray analysis and their corresponding fold change to com-
pute a normalized enrichment score (NES) for gene groupingsFig. 1. (A) Hierarchical clustering and heat map and (B) principal component analysis sh
samples. Red dots represent control samples; blue dots represent xanthophyll treated sam
and lutein/zeaxanthin treated samples and corresponding p-values. Green dots represe
gulated and 176 downregulated.based on known gene ontology sets or KEGG pathways (14). Of the
653 gene sets, 56 were signiﬁcantly up-regulated (po0.05) and
two of the top sets (Fig. 2A) were related to glycan biosynthesis:
N-glycan biosynthesis (NES¼1.776, p¼0.0054) and biosynthesis of
chondroitin sulfate (NES¼1.684, p¼0.0096) (Fig. 2B and C). An-
other 68 gene sets were signiﬁcantly down-regulated by xantho-
phyll treatment, and those with the most negative NES (Fig. 2A)
included genes related to DNA replication and mitosis.
As an alternative, we used DAVID functional annotation [15,16]
to identify pathways enriched in xanthophyll-regulated genes. The
only statistically signiﬁcantly up-regulated pathway was O-glycan
biosynthesis. Because DAVID only identiﬁed one up-regulated
pathway, we also employed ConsensusPathDB functional annota-
tion from the Max Planck Institute [17,18] to identify additional
pathways up-regulated by xanthophyll treatment. Pathways re-
lated to N-glycan, O-glycan and glycosaminoglycan synthesis and
glycosylation showed statistically signiﬁcant enrichment (Fig. 3).
3.3. Experimental validation of gene expression changes
We carried out an independent biological replicate experiment,
exposing EpiDerm to the 5:1 ratio of xanthophylls. The RNA was
analyzed using qPCR for the ten genes with the highest positive fold
change and 10 genes with the largest negative fold change. Only
three of the 10 most up-regulated genes showed positive fold change
by qPCR, notably chondroitin sulfate N-acetylgalactosaminyl-
transferase-1. On the other hand, eight of the 10 most down-regu-
lated genes showed negative fold change by qPCR, including robust
reduction of multiple peptidase inhibitors (FETUB, SPINK7, and
SERPINA12).
The GSEA gene set (Drug metabolism: cytochrome P450) had a
negative enrichment score, and this set contains multiple genesowing clear separation between gene expression of control and xanthophyll treated
ples. (C) Volcano plot maps gene expression based on fold change between control
nt genes identiﬁed as having statistically signiﬁcantly large fold change: 47 upre-
Fig. 2. (A) Top 12 pathways identiﬁed by GSEA as upregulated or downregulated by xanthophyll treatment based on NES. Closed bars represent pathways with the highest
positive NES values, and open bars represent pathways with the lowest negative NES values. Most notable are the upregulated pathways for (B) N-glycan synthesis and
(C) glycosaminoglycan biosynthesis: chrondroitin sulfate. These two gene sets are shown along with a corresponding heat map in the three control and three xanthophyll
sample.
Fig. 3. Top 10 pathways signiﬁcantly upregulated by xanthophyll treatment based
on ranking of p-values identiﬁed by CPDB.
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monooxygenases. The P450 and ﬂavin monooxygenase genes were
presented in the Human Drug Metabolism RT2 Proﬁler PCR array
that we purchased to analyze RNA from control and xanthophyll
treated EpiDerm. However, we noted that many genes in this
proﬁler array have relatively low expression levels in keratino-
cytes, and only 10 of the 84 genes in this array showed signiﬁcant
fold change in response to xanthophylls. The proﬁler array in-
cluded 16 genes that showed signiﬁcant down-regulated in the
Affymetrix analysis, but none of these were validated by the pro-
ﬁler array.3.4. Effects of xanthophylls on glycosaminoglycan production
Glycosaminoglycans (GAGs) are a class of primarily O-linked
glycans known to play a role in skin hydration and wound healing.
They can be divided into two classes: (1) sulfated, which consists
of chondroitin sulfate, dermatan sulfate, keratan sulfate, heparin
sulfate, and heparin, and (2) non-sulfated, which consists only of
hyaluronan [24].
Sulfated glycosaminoglycans (sGAGs) produced by the EpiDerm
cultures were quantiﬁed using the Blyscan dye-binding assay and
by radioactive 35S-sulfate metabolic labeling. For the Blyscan assay,
a fresh set of EpiDerm samples were treated in triplicate with
vehicle for three days (control) or xanthophylls for 1, 2, or 3 days.
Media were assayed for sGAG content (Fig. 4A). Within 24 h, the
EpiDerm produced 15 mg of sGAGs per well, which after two days
was 13 mg per well and after 3 days was 8 mg per well, compared to
7 mg per well in the untreated controls. We concluded that there
was an initial synthesis and release followed by some degradation
of the sGAGs. Total sGAG biosynthesis by these cultures was de-
termined by combining the amount released into the media plus
the amount released by papain digestion of the tissues, a standard
method used for analysis of total sGAGs (Fig. 4B). These results
showed that about half of the total sGAGs were retained in the
tissues (15 mg/well vs. 30 mg/well). Over the three days of incuba-
tion, a one-way ANOVA test showed no signiﬁcant difference be-
tween control and xanthophyll-treated samples (F(3,8)¼1.31,
Fig. 4. (A) sGAGs produced per EpiDerm well measured in the media by the Blyscan sulfated glycosaminoglycan assay (left to right: control – open bar, 1 day xanthophyll
treatment, 2 day xanthophyll treatment, 3 day xanthophyll treatment). No signiﬁcant difference between control and treated samples (p¼0.336). (B) sGAGs bound to
EpiDerm tissue released by papain digest, then measured by the Blyscan sulfated glycosaminoglycan assay (left to right: control, 1 day xanthophyll treatment, 2 day
xanthophyll treatment, 3 day xanthophyll treatment). (C) sGAG produced per EpiDerm tissue digest at 24 and 72 h measured by 35S-sulfate labeling. No signiﬁcant difference
was found between control (open bars) and treated samples (ﬁlled bars) at 24 or at 72 h (p¼0.141, p¼0.646). (D) Hyaluronan in EpiDerm tissue media at 24 h measured by
an enzyme-linked competitive binding assay (control, open bar; xanthophyll treated, ﬁlled bar). A signiﬁcant increase in hyaluronan production was found as a result of
lutein/zeaxanthin treatment (n¼3, p¼0.0019).
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We also measured sGAGs synthesis in the tissues using
35S-sulfate metabolic labeling. Triplicate samples of EpiDerm were
treated with vehicle alone or xanthophylls for either 1 or 3 days.
Tissues were removed from their inserts and washed repeatedly
with PBS to remove any unincorporated 35S, based on monitoring
radioactivity of the washes. Tissues were digested by papain to
release the sGAGs, and 35S-content was quantiﬁed for each sample
by scintillation counting. There was a greater than 50% increase in
35S incorporation between days 1 and 3, and student two-way t-
tests showed no signiﬁcant difference between 35S-incorporation
into sGAGs between control and xanthophyll treated samples at
either 1 or 3 days (p¼0.141, p¼0.646). From these experiments,
we concluded that xanthophylls did not signiﬁcantly increase the
biosynthetic production of sGAGs.
Because we did not detect any increase in the amount of sGAGs
in xanthophyll treated tissue samples compared to control sam-
ples, even though genes for these pathways were up-regulated, we
assayed for hyaluronan, the non-sulfated GAG, using a enzyme-
linked competitive binding assay with a standard curve generated
using puriﬁed hyaluronan. Triplicate samples of EpiDerm were
incubated for 1 day in control or xanthophyll supplemented
media. Medium was removed and required 10 dilution for
quantiﬁcation of the hyaluronan. Control samples averaged a
concentration of 66 ng/mL, compared to xanthophyll-treated
samples that produced 130 ng/mL (Fig. 4D). A two-way student t-
test showed a signiﬁcant increase in hyaluronan production in
response to xanthophyll supplementation (p¼0.002).
The terminal step of hyaluronan synthesis is catalyzed by three
isoforms of hyaluronic acid synthase (HAS1, HAS2, and HAS3) (25).The gene expression data from the Affymetrix array showed a
signiﬁcant increase in expression of HAS3 (log 2FC¼0.812, adj.
po0.001), but not HAS1 (adj. p¼0.630) or HAS2 (adj. p¼0.113).4. Discussion
The molecular mechanisms for the beneﬁcial changes in the
skin induced by xanthophylls (luteinþzeaxanthin) remain un-
known. In this study, we used a validated in vitro model of human
tissue, EpiDerm, to determine the effects of xanthophyll treatment
on gene expression. One advantage of this model is that cells are
grown in 3D on ﬁlters at a liquid–air interface, which promotes
differentiation while the single cell type allows side-by-side ge-
netic comparison for effects of treatments without the confound-
ing presence of lymphocytes or other cell types from the dermis or
subcutaneous layers of the skin. Bioinformatic analysis of the gene
expression data from Affymetrix arrays revealed that there were
176 genes signiﬁcantly (po0.05) down-regulated (log 2FC42)
compared to 47 genes that were signiﬁcantly up-regulated. The
down-regulated genes are in pathways for arachidonic acid and
eicosanoid metabolism and biological oxidation. In clinical trials,
lipid peroxidation was observed to decrease, and photoprotective
activity was observed to increase due to xanthophyll treatments in
clinical trials [11]. Arachidonic acid is degraded into mal-
ondialdehyde (MDA) [32,33], which was used as a measure of lipid
peroxidation in the clinical trial. Down regulation of genes in-
volved in arachidonic metabolism by xanthophylls would decrease
MDA production, supporting the clinical observations. Arachidonic
acid is also metabolized into pro-inﬂammatory eicosanoids,
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pression of genes for enzymes in these pathways is consistent with
the observed decrease in UV-induced erythema, as a measure of
photoprotective activity by xanthophylls seen in clinical trials. We
also note that the genes down-regulated by xanthophylls include a
number of serpin protease inhibitor genes. Of the most down-
regulated genes, a majority that were in a secondary PCR array
were validated, including genes encoding extracellular peptidase
inhibitors (FETUB, SPINK7, and SERPIN A12). Reduced levels of
these proteins may be related to remodeling of skin [35].
Analysis of up-regulated genes pointed to enhancement of
pathways for glycosaminoglycan biosynthesis. We directly assayed
the biosynthetic products of these pathways. We found no evi-
dence for xanthophyll-induced increase in production of sulfated
glycosaminoglycans. On the other hand, there was a signiﬁcant,
almost 2-fold increase in the production of hyaluronic acid (hya-
luronan), a non-sulfated glycan. We note that the amount of
hyaluronan released into the medium was only a fraction of the
amount of sGAGs released by the EpiDerm system. It is possible
that hyaluronan remained associated with the cells. Xanthophyll
induction of hyaluronan synthesis likely corresponds to the clinical
observation that skin hydration and elasticity were signiﬁcantly
improved by xanthophyll treatments [11]. Hyaluronan is known to
have high water-binding capacity and therefore plays an im-
portant role in maintaining skin hydration. There is also evidence
that hyaluronan can act as a signaling molecule in response to
injury to induce wound repair, and as a free radical scavenger to
prevent damage to the skin [25–28]. In cultured human kerati-
nocytes expression of HAS3 was reported as low relative to HAS1,
but stimulated by addition of HB-EGF [36]. A previous study by
Sayo et al. [29] demonstrated that a number of non-provitamin A
carotenoids, including lutein and zeaxanthin, induced hyaluronan
synthesis and expression of HAS3 in human foreskin keratino-
cytes. Lutein and its metabolites have been proposed to act via
retinoic acid receptors (RARs) to increase HAS3 mRNA and hya-
luronan biosynthesis [29–31].
We used the oPOSSUM algorithm to perform analysis of tran-
scription factors for the 47 genes most highly induced by xan-
thophylls. The statistical analysis produces a Z score, which is the
number of standard deviations above or below the expected rate
of occurrence of a transcription factor binding site [19–21]. The
transcription factors PPARG:RXRA (Z¼11.1) and RXR:RAR_DR5
(Z¼9.90) had the highest Z-scores. We speculate that these two
transcription factors may play a role in the up regulation of xan-
thophyll-induced genes. Consistent with this concept, we found
relatively high expression levels for these transcription factors,
PPARG (average expression¼7.1) and RXRA (average ex-
pression¼10.4), in the RNA extracted from EpiDerm. Whether
xanthophylls act as ligands for these or other transcription factors
is not known. Because many more genes are down-regulated vs.
up-regulated by xanthophylls one has to suspect that whatever
proteins are acting as receptors for xanthophylls, these ligands are
promoting recruitment of co-repressors as part of their mechan-
ism of action.5. Conclusions
The xanthophylls lutein plus zeaxanthin alter gene expression
in an in vitro model of human skin and these changes provide a
mechanistic basis of the clinical beneﬁts of xanthophylls.Acknowledgments
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